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A B S T R A C T
55 year old women came to me as her family doctor, seeking advice on mammography screening. She rather wouldn’t
do it because she feels well, is a bit afraid of radiation and thinks it’s not important, since she doesn’t have individual
risk. Having in mind newly emerging evidence about the questionable value of the screening, especially in women with-
out any risks, I was in dilemma what to recommend. Therefore, we did a limited literature search. Systematic reviews
are questioning effectiveness of mammography as screening method, evidences show limited effect on reducing mortality
and the burden of overdiagnosis and overtreatmnent. Professional recommendations vary from country to country. Over-
all impression is that many questions remain open and, until better method of screening is found, the decisions about
breast cancer screening should be strongly individualized, according to the patients risks. We openly discussed it, she de-
cided to postpone mammography for a while.
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Introduction
The incidence and mortality of breast cancer in Croa-
tia is continuously increasing, although in recent years
there has been stabilization in mortality trend1. The in-
dividual consultations and education on risk factors, as
well as education on self-examination and breast exami-
nation, are the preventive measures to be undertaken by
family doctors (FD) and gynecologist as it was defined by
the Plan and Programs of Health Care Measures, Cro-
atian standards for health care delivery2. Additionally,
from 2006 the Ministry of Health and Social Welfare is
conducting the National screening program for early de-
tection of breast cancer, »Mamma«, which includes mam-
mography every two year for women aged 50–69 years3.
By post to home address, women from the target group
receive the invitation letter with the date, time and place
where they should do the mammogram. There is also a
phone number they should call if they have already per-
formed mammography for any reason, within two years.
Case Report
55 year old women received a letter for screening
mammography by post and presented it to me as her cho-
sen FD, with concerns about the procedure. Although
she has never had a mammography, she rather wouldn’t
do it because she feels well, is a bit afraid of radiation and
doesn’t perceive it as important in general, since there is
no family history of breast or ovarian cancer. She deliv-
ered babies twice, breast-feeds, never smoked, is not
obese, and hasn’t taken any pills including contraceptive
and menstrual bleeding stopped five years ago.
At that moment, I was rather confused having in
mind newly emerging evidence about the questionable
value of mammography, especially in women without any
risks. I know her very well; she is my patient more than
ten years, a responsible one, usually taking care about
herself and her family, never in panic. Therefore, we
openly discussed the good intention of Mamma program
on one side, and new evidence, on another side. At the
end she decided to postpone mammography for a while.
Discussion and Conclusions
Current recommendations on mammography screen-
ing vary from country to country. The increased number
of countries with a long tradition is actually questioning
the effectiveness of the program. In the UK, screening is
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carried out since 1985, it is considered annually prevent-
ing 1,300 deaths, and National Health Service (NHS) de-
cided that screening is beneficial and should be conti-
nued4. Swiss Medical Board recommended in February
2014 to reject the screening program for breast cancer
because it leads to too much unnecessary interventions.
From their calculations, systematic mammography saves
1–2 women per 1000 mammograms done, but leads to
unnecessary tests and procedures for the 100 women per
1000 screened once5. A similar situation is with two main
agencies dealing with preventive services. US Preventive
Task Force specially noticed at their web-pages that the
recommendations for mammography screening to all wo-
men aged 50–74 are currently under revision6. In The
Canadian Task Force recommendations from the years
2011, mammography screening to all women from 50–74
years was included7. But, they also pointed out that a
quality of evidence was week.
There are two serious reasons to question the use of
mammography screening to all women aged 50–69. The
first is effectiveness of mammography as screening me-
thod and second is the possibilities of overdiagnosis and
overtreatmnent. Although it was believed that mammog-
raphy would save a large number of women’s lives, re-
cently published studies do not support this notion7,8. In
Canada, in 15 screening centers, around 90 000 women
from 40 to 59 years were followed up through five years.
The results indicated there was no reduced mortality in
those screened with mammography compared to the con-
trol group followed by usual care7,8. However, a number
of full or partial mastectomies were significantly higher
in the mammography group. Observational studies sug-
gest an even greater occurrence of over-diagnosis in
women who have undergone screening 9. A Swedish
study of mortality indicates that mammography screen-
ing program introduced in 1974, with the highest re-
sponse rate from 75 to 85%, has limited or no effect on re-
ducing mortality10. The same conclusion was made in
Denmark in a study of regions where screening was im-
plemented, compared to those without the programs11.
The similar situation was observed in Norway12. It is well
documented that the incidence of breast cancer is reduc-
ing in the Western countries, so the International Pre-
vention Research Institute (IPRI) sought confirmation
that it is the impact of the mammography screening pro-
grams. But the study that included countries in which
the program is implemented at least 7 years, with mini-
mum response rate of 60%, did not show the expected de-
crease in the incidence of invasive breast cancer13.
Retrospective analysis of WHO statistics data on mor-
tality trends in 30 European countries also showed that
breast cancer mortality has continued to fall in Western
countries from 1990. It was considered to be a primarily
result of a newer and effective treatment options and ef-
ficacy of the health care system in those countries. The
results have shown that in Central European countries
additional efforts have to be made, because there is con-
tinuously increasing mortality. It is considered mainly
due to poor efficiency of health care services, including a
small number of diagnostic equipment available and
lower availability of newer drugs14,15. The experiences of
some European countries, particularly France, indicate
that it is more important to invest in new methods of
treatment than in new screening methods16–18.
Therefore, until better method of screening is found,
the decisions about breast cancer screening should be
strongly individualized, firstly oriented to the patients
under the risks. Additionally, many questions remain un-
answered and further research has to be done, especially
those important for everyday practice19.
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MAMOGRAFIJA KOD @ENA KOJE NISU RIZI^NE ZA RAZVOJ KARCINOMA DOJKE
S A @ E T A K
55-godi{nja `ena obratila mi se kao obiteljskoj lije~nici, tra`e}i savjet o probiru mamografijom. Nije sklona pretrazi
jer se dobro osje}a, malo se boji zra~enja, i ne smatra ju bitnom s obzirom da nema individualni rizik. Imaju}i u vidu
nove dokaze o upitnoj vrijednosti probira mamografijom, posebice u `ena bez rizika, bila sam u nedoumici {to preporu-
~iti. Zato smo dodatno provjerili pretra`ivanjem literature. Sustavni pregledi istra`ivanja dovode u pitanje u~inkovitost
mamografije kao metode probira, s obzirom na dokaze o ograni~enom u~inku na smanjenje smrtnosti i teret preko-
mjernog dijagnosticiranja te zahvata. Trenutne profesionalne preporuke o probiru mamografijom variraju od zemlje do
zemlje. Ukupni dojam je da mnoga pitanja ostaju neodgovorena, potrebna su daljnja istra`ivanja, te, dok se ne prona|e
bolja metoda probira, odluka o probiru treba biti individualizirana, orijentirana prema individualnom riziku pacijen-
tice. Otvoreno smo o tome porazgovarale, pacijentica je odlu~ila zasad odgoditi mamografiju.
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